• ATIP is downregulated in prostate cancer tissues and negatively correlates with patient disease-free survival, suggesting its role as a tumor suppressor.
• Silencing ATIP promotes mitochondrial fission and enhances prostate cancer cell migration and invasion, linking mitochondrial dynamics to metastasis.
• Reconstitution of ATIP1 in ATIP-deficient cells attenuates mitochondrial trafficking and tumor cell movement, confirming its inhibitory function.
• ATIP1 emerges as a potential prognostic biomarker and therapeutic target for prostate cancer metastasis.